RGS Protein

CCG-63802 is a reversible inhibitor of regulator of G-protein signaling (RGS) proteins. Selective amongst RGS proteins, with greatest potency at RGS4.

CCG-63808 is a reversible inhibitor of regulator of G-protein signaling (RGS) proteins.

CCG 50014 is a potent and selective inhibitor of RGS4 with IC50 of 30 nM.

Regulator of G-Protein Signaling 19 Human Recombinant

Regulator of G-Protein Signaling 2 Human Recombinant

Regulator of G-Protein Signaling 1 Human Recombinant

Regulator of G-Protein Signaling 14 Human Recombinant

Regulator of G-Protein Signaling 16 Human Recombinant

Regulator of G-Protein Signaling 10 Human Recombinant

Regulator of G-Protein Signaling 21 Human Recombinant

Regulator of G-Protein Signaling 4 Human Recombinant

Regulator of G-Protein Signaling 5 Human Recombinant

Regulator of G-Protein Signaling 17 Human Recombinant

CCG 203769 is a selective inhibitor of the regulator of G protein signaling (RGS4), effectively disrupting the RGS4-Gαo protein-protein interaction with an IC50 of 17 nM. This compound is instrumental for research applications focused on G protein-coupled signaling pathways and the modulation of G protein activity. CCG 203769 may be utilized in studies exploring the role of RGS proteins in various physiological processes and disease states.

BMS-192364 is a selective RGS (Regulator of G Protein Signaling) agonist that targets the Gα-RGS interaction, promoting the formation of an inactive Gα-RGS complex. This compound has been shown to reduce urinary bladder contraction and enhance the activity of GTPase-activating proteins (GAPs) on Gq proteins. Additionally, BMS-192364 inhibits calcium flux, making it a valuable tool for studying signaling pathways involved in bladder function and related physiological processes.

RGS10 modulator-1 functions as a potent modulator of the RGS10 protein, exhibiting significant biological activity by reversing interferon-gamma (IFNγ)-induced expression of RGS10 protein and mRNA. Additionally, this compound effectively reduces the levels of COX-2 mRNA and inducible nitric oxide synthase (iNOS) expression that are stimulated by IFNγ. RGS10 modulator-1 is a valuable tool for research exploring the regulatory mechanisms of RGS10 in inflammatory responses and related signaling pathways.

Z55660043 is a selective inhibitor of Regulator of G protein Signaling-14 (RGS14) with an IC50 of 2.3 μM. This compound acts by non-covalently inhibiting the GTPase-accelerating protein (GAP) activity of RGS14, demonstrating a favorable safety profile without significant cytotoxic effects. Z55660043 is suitable for research focused on central nervous system and metabolic disorders, contributing to the understanding of RGS14's role in these biological processes.

CCG-2046 is a selective inhibitor of the regulator of G-protein signaling 4 (RGS4), demonstrating an IC50 value of 4.3 μM for inhibiting the RGS4-Gαo interaction. This compound modulates G-protein signaling pathways, making it a valuable tool for studying their role in various physiological processes. CCG-2046 is suitable for research applications focused on neurobiology, cardiac function, and potential therapeutic interventions for related disorders.

CCG-4986 is a selective RGS protein inhibitor that covalently modifies the Cys-132 residue of RGS4, thereby inhibiting its activity. This compound is valuable for studying the implications of altered G protein-coupled receptor (GPCR) signaling in various pathological conditions, including Parkinson's disease and opioid addiction. CCG-4986 is a useful tool for researchers investigating the role of RGS proteins in cellular signaling pathways.